Thank you for visitingThe Mortgage Marketplace Inc.
We hope you'll give us the opportunity to finance your new purchase or to refinance your existing loan. Our reputation is extremely important to us and we promise your experience with The Mortgage Marketplace will be a pleasant one. The interest rate and fees will always be upfront and there will never be any unexpected changes or surprises at closing.
We offer true no-cost loans. This means that if we quote you a no-cost loan, then there will be absolutely no closing costs - which include lender fees, title fees and appraisal fees. But there are so many combinations of rates and fees, so if you decide you'd rather pay some of the closing costs or even want to pay discount points to get a lower rate, we'll let you know your options for that as well.
At The Mortgage Marketplace, every loan and borrower becomes a top priority so we'll get your loan closed fast. With 24-48 hour loan approvals you will always be kept up to date on the status of your loan and with the discount pricing we get from our lenders, we'll always pass on those savings to you, the consumer!
Please call us now at 847-737-4747 and see for yourself why we receive so many "thank you" emails like these:
"Also, thank you for the smoothest refi we've ever done. You made the process painless, from beginning to end. I will be recommending you to other people I know who are interested in refinancing. Thank you."
"I will be sure to store this information and refer you to anyone I know of needing financing. I was overly impressed by how wonderful you were through the entire process. Thanks again and good luck! I'm sure I will be using you again sometime soon!"
You did a job well beyond what most would do to take care of us. I will keep your info and recommend to anyone I hear wanting to refinance."
U.S. pharmaceutical giant Pfizer has approached British rival AstraZeneca to propose a 60 billion pound ($101 billion) takeover, the Sunday Times reported on Sunday. The paper said, citing senior investment bankers and industry sources, that informal conversations about a deal had taken place between the two firms but that no talks were currently under way after AstraZeneca resisted the approach. AstraZeneca is Britain's second-biggest pharmaceuticals group with a current market valuation of around $80 billion, compared with Pfizer, which is valued at $193 billion, according to Thomson Reuters data. Earnings at AstraZeneca fell 6 percent in the fourth quarter of 2013, and the drugmaker has said it expects them to keep falling in 2014 as generic competition to Nexium, its popular heartburn and ulcer drug, takes a big bite out of U.S. profits from late May. AstraZeneca has suffered a dry period in drug discovery in recent years and badly needs to find new medicines to replace blockbusters such as Nexium and Crestor, a treatment for high cholesterol that will lose patent protection in a few years.
The refinancing you handled worked out well for us. Everything came to pass just as you said it would. If I have friends who are thinking about refinancing, I will recommend you."